ClinicalTrials.gg
WithdrawnNCT01586286Updated May 22, 2014

A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain

An interventional study of Nifedipine and Placebo Ointment Base in Levator Ani Syndrome, sponsored by Vanderbilt University. Withdrawn at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-22.

Sponsored by Vanderbilt University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
No patients were recruited over a 12 month period

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.

Enrollment
117th of 124
0 · median 50
Started
2012
with 7 others
No phase
72 of 152
23 open now
Registered
48th of 152
by date

Among the 152 studies in Pelvic Pain with a site in United States, this one is the 117th largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2012, is one of 72 with no phase, and was the 48th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pelvic Pain with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to perform a randomized controlled trial among female patients with a diagnosis of pelvic floor hypertonus (extreme muscle tension) with associated pain, dysfunctional voiding, dyspareunia, and/ or obstructed defecation.

Read the detailed description

Given the paucity of information and the magnitude of debilitation that can be associated with chronic pain syndromes, the potential to ameliorate pain and successfully treat these symptoms is an area that merits further exploration. In this study, we hypothesize that the addition of vaginal nifedipine to a physical therapy protocol will result in greater treatment success than treatment with physical therapy alone.

The objective is to perform a randomized controlled trial among female participants with a diagnosis of pelvic floor hypertonus with associated pain, dysfunctional voiding, dyspareunia, and/or obstructed defecation. Group 1 will serve as the control and will undergo pelvic floor physical therapy and placebo (lanolin and mineral oil base). Group 2 will also undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.

Specific aims include:

  1. Comparison of subjective outcome measures, specifically quality of life metrics scales: Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and validated 11-point pain scale.
  2. Comparison of objective outcome measures, specifically a validated digital assessment of pelvic floor strength: the Oxford scale.

Group 1 will serve as the control and will undergo pelvic floor physical therapy and placebo (lanolin base). Group 2 will also undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine. We will collect data on these patients to determine if the treatment of vaginal nifedipine with physical therapy provides a more successful treatment for this pelvic floor dysfunction.

03

Conditions studied

  • Levator Ani Syndrome

Keywords

  • Levator Myalgia
  • Pelvic Pain
  • Vaginismus
  • Myofascial pain syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has levator myalgia upon appropriate pelvic exam that reproduces HPI pain
  • Subject has symptoms such as voiding dysfunction, dyspareunia, vaginismus, or obstructed defecation
  • Subject is willing and able to give written consent for the study
  • Subject is willing to undergo treatment with pelvic physical therapy \& vaginal nifedipine
  • Subject is able to speak, read, and write in English
  • Subject is at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Subject has previously diagnosed interstitial cystitis
  • Subject has an active case of symptomatic HSV, syphilis, or shingles
  • Subject has a history of uncontrolled hypertension
  • Subject is already taking a calcium channel blocker
  • Subject has a history of MI, CHF, or arrhythmia
  • Subject has a history of neurologic disease
  • Subject has a history of congenital or progressive musculoskeletal disease
  • Subject has a history of bladder or pelvic cancer and/or pelvic radiation
  • Subject is planning to be or currently pregnant
  • Subject has known allergy or adverse reaction to nifedipine
  • Subject has known allergy or adverse reaction to lanolin, mineral oil, petrolatum
  • Subject is undergoing pharmacologic treatment specific to pelvic pain
  • Subject is taking oral beta adrenergic antagonist medication
  • Subject has an active pelvic or vaginal infection
  • Subjects with hypotension on screening physical examination (i.e. confirmed SBP\<90 mmHg or DBP\<60 mmHg).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Ointment Base

    Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).

    Drug: Placebo Ointment Base

  • Active comparator
    Nifedipine Ointment

    Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.

    Drug: Nifedipine

Interventions

  • Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area

  • DrugPlacebo Ointment Base

    Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area

06

What researchers measure

Primary outcomes

  1. Improvement in Quality of Life

    The primary outcome will measure quality of life metrics, as reported by the patient herself. We will use the following validated instruments: Pelvic Floor Distress Inventory, Pelvic Floor Impact Questionnaire, and validated 11-point pain scale. The aim is to measure whether the patient experienced improvement in her symptoms when vaginal nifedipine was administered (in addition to physical therapy).

    Time frame: To be assessed 1 month post-treatment.

Secondary outcomes

  1. Improvement in Hypertonic Pelvic Floor Muscles

    The secondary outcome measure will be assessed and reported by the healthcare provider at the above visits. After instructing the patient to voluntarily relax the pelvic floor muscles, the resting tone will be measured using the Oxford scale, which is a validated digital assessment.

    Time frame: To be assessed at baseline and the following post-treatment intervals: 1, 2, 3, and 6 months

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

References and documents

Publications

  • Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996 Mar;87(3):321-7. doi: 10.1016/0029-7844(95)00458-0. PubMed 8598948 ↗
  • Reiter RC. A profile of women with chronic pelvic pain. Clin Obstet Gynecol. 1990 Mar;33(1):130-6. No abstract available. PubMed 2178830 ↗
  • Butrick CW. Pelvic floor hypertonic disorders: identification and management. Obstet Gynecol Clin North Am. 2009 Sep;36(3):707-22. doi: 10.1016/j.ogc.2009.08.011. PubMed 19932423 ↗
  • Rosenbaum TY, Owens A. The role of pelvic floor physical therapy in the treatment of pelvic and genital pain-related sexual dysfunction (CME). J Sex Med. 2008 Mar;5(3):513-23; quiz 524-5. doi: 10.1111/j.1743-6109.2007.00761.x. PubMed 18304280 ↗
  • Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992 May;49(2):205-219. doi: 10.1016/0304-3959(92)90144-Z. PubMed 1535121 ↗
  • Bornstein J, Tuma R, Farajun Y, Azran A, Zarfati D. Topical nifedipine for the treatment of localized provoked vulvodynia: a placebo-controlled study. J Pain. 2010 Dec;11(12):1403-9. doi: 10.1016/j.jpain.2010.03.016. Epub 2010 May 26. PubMed 20537958 ↗
  • Katsinelos P, Papaziogas B, Koutelidakis I, Paroutoglou G, Dimiropoulos S, Souparis A, Atmatzidis K. Topical 0.5% nifedipine vs. lateral internal sphincterotomy for the treatment of chronic anal fissure: long-term follow-up. Int J Colorectal Dis. 2006 Mar;21(2):179-83. doi: 10.1007/s00384-005-0766-x. Epub 2005 Aug 10. PubMed 16091912 ↗
  • Nelson R. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003431. doi: 10.1002/14651858.CD003431.pub2. PubMed 17054170 ↗
  • Hundley AF, Wu JM, Visco AG. A comparison of perineometer to brink score for assessment of pelvic floor muscle strength. Am J Obstet Gynecol. 2005 May;192(5):1583-91. doi: 10.1016/j.ajog.2004.11.015. PubMed 15902162 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2012
First posted
Apr 26, 2012
Start
Jul 2012
Primary completionEst.
May 2014
CompletionEst.
May 2014
Last update
May 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01586286
Responsible party
Daniel Biller (Assistant Professor, Vanderbilt University) — Principal investigator
First posted
Apr 26, 2012
Start date
Jul 2012
Primary completion
May 2014 (estimated)
Completion
May 2014 (estimated)
Last update
May 22, 2014

Study contacts

Daniel Biller, MD
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion